For children with febrile urinary tract infection (UTI), stopping antibiotic treatment 3 days after clinical improvement ...

Urinary tract infections (UTIs ... has approved Blujepa (gepotidacin), a new oral antibiotic from GSK, offering fresh hope for those struggling with recurrent and drug-resistant UTIs.

"We are proud to have developed Blujepa, the first in a new class of oral antibiotics for [uncomplicated UTIs] in nearly ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.

The FDA has approved Blujepa (gepotidacin), a first-in-class oral antibiotic for uncomplicated urinary tract infections (uUTIs) in women and children aged 12 and older. Clinical trials showed its ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract ...

for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older. The small-molecule drug is the first in a new class of oral antibiotics for ...

"We are proud to have developed Blujepa, the first in a new class of oral antibiotics for (uncomplicated UTIs) in nearly ...

the first in a new class of oral antibiotics for [uncomplicated UTIs] in nearly three decades, and to bring another option to patients given recurrent infections and rising rates of resistance to ...

Known for spending much of its life underground, the little-known American burying beetle could hold the key to developing ...